Veterinary Cancer Care is committed to furthering the field of oncology by participating in and initiating clinic trials research. In addition to collecting data on our own patients, Veterinary Cancer Care continually monitors new developments in cancer research. Being informed of the most recent progress in veterinary cancer and innovative methods of managing the disease is of tremendous benefit to our clients.
Immunocidin™ is the mycobacterial cell wall fraction derived from non-pathogenic Mycobacterium phlei. It is currently approved for the treatment of mammary cancer in dogs. We are currently partnering with NovaVive to gather information on the efficacy of Immunocidin™ in various other cancers.
Mycobacteria, especially their cell walls, have been known for many years to be active against a variety of tumors. Immunocidin™ is an emulsion of mycobacterial cell wall fractions which have been modified to reduce their toxic and allergic effect but retain their immunomodulatory and anti-tumor activity. Immunocidin™ stimulates the activation of a variety of cytokines and lymphocytes which in turn display potent anti-tumor activity. Immunocidin™ may be used for other cancer types which is considered extra-label drug use is in accordance with the Animal Medical Drug Use Clarification Act (AMDUCA).
Dr. Kelly will be presenting data on this study at the ACVIM conference in Seattle, June 14-16, 2018!
Intralesional Chemotherapy Clinical Trial
Intralesional chemotherapy is the administration of cancer fighting drugs directly into the tumor, tumor site, or adjacent tissues. The goal is to provide local tumor control by achieving high local chemotherapeutic drug concentrations. Because the chemotherapy is not given into a vein, the side effects tend to be few. The advantages are ease of administration, low risk of side effects, low cost, and the option for subsequent treatments in the event of a tumor recurrence.
For additional information regarding the use of intralesional chemotherapy to treat acanthomatous ameloblastoma in dogs please see our publication:
Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin.
Veterinary and Comparative Oncology, Volume 8, Issue 2, pages 81–86, June 2010
Intralesional 5-Fluorouracil treatment for Soft Tissue Sarcoma in Dogs
Soft tissue sarcomas (STS) are a group of similarly behaving cancers that account for 15% of the tumors of skin and subcutaneous tissue in dogs. The most effective treatment for STS is wide surgical excision (removing the tumor and several centimeters of the surrounding tissue) followed by radiation. Radiation can be logistically challenging and financially challenging. 5-Florouracil (5-FU) is a commonly used systemic chemotherapy drug that has shown promise as a local (intralesional) treatment alternative to radiation. At Veterinary Cancer Care we are concluding a six-year preliminary trial of intralesional 5-FU post-surgery in dogs with STS. If proven effective, this would provide a lower cost alternative to radiation therapy available to all veterinarians. We hope to publish results in the near future. While we compile data for publication we are continuing to offer this treatment.
For currently published results using 5-FU in dogs with STS see the following publication:
Postsurgical intra-incisional 5-Fluorouracil in dogs with incompletely resected, extremity malignant spindle cell tumours: A Pilot Study.
Veterinary and Comparative Oncology, Volume 5, Issue 4, pages 239–249, December 2007